Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2971482 | 0.84 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL2820968 | 0.83 | HCAR3 (0.31) | TRPA1 | |
| SCHEMBL2976305 | 0.73 | SCN9A (0.36) | TGFBR1 | |
| SCHEMBL2972441 | 0.72 | JAK2 (0.34) | — | |
| SCHEMBL2976329 | 0.72 | CYP2D6 (0.32) | — | |
| SCHEMBL2980377 | 0.69 | CES2 (0.38) | — | |
| SCHEMBL2819999 | 0.68 | PIM3 (0.31) | — | |
| SCHEMBL7433691 | 0.68 | ALDH1A1 (0.49) | TGFBR1 | |
| SCHEMBL2819732 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL2822349 | 0.66 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | TGFBR1 2223/4885TRPA1 716/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | TGFBR1 2223/4885TRPA1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.